Core Viewpoint - Orion Corporation has upgraded its full-year outlook for 2025 due to better-than-expected product sales and royalty income in the first half of the year, which is anticipated to continue for the remainder of the year [1][2]. Financial Outlook - The new full-year outlook estimates net sales to be between EUR 1,630 million and EUR 1,730 million, and operating profit to be between EUR 400 million and EUR 500 million [3]. - The previous outlook estimated net sales between EUR 1,550 million and EUR 1,650 million, and operating profit between EUR 350 million and EUR 450 million [4]. Milestone Payments - The 2025 outlook does not include any material milestone payments, although Orion is entitled to receive a milestone payment of EUR 180 million from Bayer related to the sale of Nubeqa® [2]. - There is uncertainty regarding the timing of this milestone payment, which is why it has not been included in the 2025 outlook estimate [2].